Metis Global Partners LLC Purchases 4,283 Shares of Johnson & Johnson (NYSE:JNJ)

Metis Global Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 138,758 shares of the company’s stock after acquiring an additional 4,283 shares during the period. Johnson & Johnson comprises about 0.7% of Metis Global Partners LLC’s investment portfolio, making the stock its 21st biggest position. Metis Global Partners LLC’s holdings in Johnson & Johnson were worth $22,487,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Curi RMB Capital LLC increased its holdings in shares of Johnson & Johnson by 2.2% during the third quarter. Curi RMB Capital LLC now owns 104,083 shares of the company’s stock worth $16,868,000 after buying an additional 2,239 shares in the last quarter. Planning Capital Management Corp grew its holdings in Johnson & Johnson by 1.0% during the 3rd quarter. Planning Capital Management Corp now owns 30,124 shares of the company’s stock worth $4,882,000 after acquiring an additional 309 shares during the period. Wealthstream Advisors Inc. lifted its stake in Johnson & Johnson by 14.6% in the third quarter. Wealthstream Advisors Inc. now owns 1,820 shares of the company’s stock valued at $295,000 after buying an additional 232 shares during the period. Zions Bancorporation N.A. raised its position in shares of Johnson & Johnson by 671.1% in the 3rd quarter. Zions Bancorporation N.A. now owns 22,525 shares of the company’s stock valued at $3,650,000 after acquiring an additional 19,604 shares during the period. Finally, BCM Advisors LLC boosted its position in shares of Johnson & Johnson by 0.5% during the third quarter. BCM Advisors LLC now owns 39,736 shares of the company’s stock worth $6,288,000 after purchasing an additional 188 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.0 %

NYSE:JNJ opened at $153.26 on Thursday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average price is $161.82 and its two-hundred day moving average price is $155.99. The firm has a market capitalization of $368.99 billion, a price-to-earnings ratio of 22.18, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm earned $2.66 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Wells Fargo & Company increased their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.